Biosynex completed the acquisition of a 75% stake in Medkoncept.

Biosynex, a manufacturer and provider of rapid membrane tests in the in-vitro diagnostic market, completed the acquisition of a 75% stake in Medkoncept, a company delivers healthcare services and products. Financial terms were not disclosed. "We are very pleased with this acquisition alongside founders in the company MEDKONCEPT, which allows us to be present on the market of the countries Nordic countries representing nearly 28m inhabitants with high purchasing power. After BHR in the UK, MEDKONCEPT in Denmark and BIGIX in Italy, BIOSYNEX will continue this acquisition strategy in other areas in Europe both in the field of diagnostics and OTC,” Larry Abensur, Biosynex CEO.